Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report
Article Sidebar
August 6, 2021
March 8, 2022
July 18, 2022
Abstract
Remdesivir is a commonly used antiviral drug to treat COVID-19. Remdesivir has some side effects; however, whether it has any effect on cardiac is rarely reported. A 44-year-old woman with symptomatic confirmed COVID-19 was treated with intravenous remdesivir 200 mg on day one and followed with 100 mg remdesivir until day five. Three days after the treatment, she had significant bradycardia shown on the electrocardiography; however, the patient had no complaint or symptom regarding the bradycardia. Based on the discussion with the cardiology team, it was decided to cease remdesivir and replace it with oseltamivir, and the ECG showed some improvement. Remdesivir is a drug that should be used safely and cannot be taken at home, as there may be side effects left unaware.Â
References
Hafeez Y, Grossman SA. Sinus Bradycardia. 2021. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
FDA Approves First Treatment for COVID-19 [Internet]. fda.gov. 2021 [cited 11 July 2021]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
Brown A, Won J, Graham R, Dinnon K, Sims A, Feng J et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Research. 2019; 169:104541.
Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug remdesivir: An update. Biomedicine & Pharmacotherapy. 2020; 130:110532.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine. 2020;382(24):2327-2336.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569-1578.
Sanchez-Codez M, Rodriguez-Gonzalez M, Gutierrez-Rosa I. Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection. European Journal of Pediatrics. 2021;180(5):1627-1627.
Gubitosa J, Kakar P, Gerula C, Nossa H, Finkel D, Wong K et al. Marked Sinus Bradycardia Associated with Remdesivir in COVID-19. JACC: Case Reports. 2020;2(14):2260-2264.
Gupta A, Parker B, Priyadarshi V, Parker J. Cardiac Adverse Events with Remdesivir in COVID-19 Infection. Cureus. 2020;12: e11132.
Day L, Abdel-Qadir H, Fralick M. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man. Canadian Medical Association Journal. 2021;193(17): E612-E615.
Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Current Emergency and Hospital Medicine Reports. 2013;1(2):83-97.
Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine. 2020;383(19):1813-1826.
Pan H, Peto R, Karim Q, Alejandria M, Henao-Restrepo A, GarcÃa C et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. N Engl J Med. 2021; 384:497-511
National Institutes of Health. Therapeutic Management of Hospitalized Adults With COVID-19 [Internet]. covid19treatmentguidelines. 2021 [cited 14 July 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/
WHO recommends against the use of remdesivir in COVID-19 patients [Internet]. Who.int. 2021 [cited 14 July 2021]. Available from: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients
Pelleg A, Belhassen B. The mechanism of the negative chronotropic and dromotropic actions of adenosine 5′-triphosphate in the heart: an update. J Cardiovasc Pharmacol 2010;56:106–9.
Authors
Qanun Medika by FK UM Surabaya is liscence under Lisensi Creative Commons Atribusi 4.0 Internasional.
